Peaks: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://peakscurative.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide drug products.

1. 1

   “The compounded semaglutide products displayed on your website identify “Peak Now” on the pictured label, suggesting Peak Now is the compounder of those drugs when in fact it is not.”

2. 2

   ““This FDA-approved treatment promotes safe, effective weight loss, helping you reduce up to 20% of your body weight and maintain long-term results.””

3. 3

   ““Clinically proven to aid in significant weight loss in overweight adults.” “Safe, affordable, and effective.” “The compounded products offered on PeaksCurative.com use FDA approved active pharmaceutical ingredients (API).””

4. 4

   “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

peakscurative.com returned a live storefront when we checked in August 2026, still selling a weight-loss line among a wider sexual-health and wellness catalogue. Neither semaglutide nor the Peak Now name appeared on the homepage at that check, though we did not review the whole site.

One of the four claims here is more technical than the rest and deserves separating out, because it is the version a well-informed shopper is most likely to accept: the products "use FDA approved active pharmaceutical ingredients (API)". Approval in the FDA sense attaches to a finished drug product, not to an ingredient in isolation, so an API-level approval claim describes something that does not exist in the form the sentence implies. Around it sit the three claims that need no unpicking at all — FDA-approved treatment, clinically proven, safe. The most useful thing to take from this letter is that the sophistication of a claim is no guide to its accuracy, and that "affordable" was the one word in "safe, affordable, and effective" FDA had no argument with.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Peaks failed to respond.